High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

Authors:

Abstract
Aims: Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective: To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care or endocrinology clinics. Materials and Methods: 798 participants recruited from outpatient clinics were risk‐stratified by NIS2+ into low‐risk, intermediate‐risk or having at‐risk MASH (NIS2+ score < 0.46, ≥ 0.46 and < 0.68 or ≥ 0.68, respectively). Presence of steatosis (CAP ≥ 288 dB/m) and clinically significant liver fibrosis (VCTE‐ ≥ 8.0 kPa) was established by transient elastography (FibroScan). Results: At‐risk MASH affected 29% of individuals with both obesity and T2D compared to 3% of those without either condition ( p < 0.001). People with at‐risk MASH, compared to those at low‐risk, more often had steatosis (81% vs. 40%), clinically significant fibrosis (42% vs. 5%), AST or ALT ≥ 40 IU/L, hepatic insulin resistance (by HOMA‐IR) and adipose tissue insulin resistance (by adipo‐IR) (all p < 0.001). NIS2+ strongly correlated with diagnosis of at‐risk MASH by FAST ( r = 0.67; p < 0.001), as well as CK‐18, ALT and AST and liver fibrosis by VCTE‐LSM (all p < 0.001). Conclusion: The prevalence of at‐risk MASH is high in individuals with obesity and T2D attending outpatient primary care and endocrinology clinics. Their progression to cirrhosis may be prevented with early risk‐stratification and timely intervention.
Funding Information
  • National Institutes of Health (DK‐120331)

This publication has 45 references indexed in Scilit: